Skip to main content

Sebastian Schneeweiss
Associate Professor of Medicine and Epidemiology at Harvard Medical School and Vice Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics of the Dept. of Medicine, Brigham and Women’s Hospital, Brigham and Women’s Hospital, Division of Pharmacoepidemiology and Pharmacoeconomics

Website

Sebastian Schneeweiss is Associate Professor of Medicine and Epidemiology at Harvard Medical School and Vice Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics of the Dept. of Medicine, Brigham and Women’s Hospital.

He is Principal Investigator of the BWH DEcIDE Research Center on Comparative Effectiveness Research and the DEcIDE Methods Center both funded by AHRQ and Director of the Harvard-Brigham Drug Safety Research Center funded by FDA/CDER. His research is funded by multiple NIH grants and focuses on the comparative effectiveness and safety of biopharmaceuticals and analytic methods to improve the validity of epidemiologic studies using complex healthcare databases particularly for newly marketed medical products. His work is published in high-ranking journals and was featured in Discover Magazine.

Dr. Schneeweiss is Past President of the International Society for Pharmacoepidemiology and is Fellow of the American College of Epidemiology, the American College of Clinical Pharmacology, and the International Society for Pharmacoepidemiology. He is voting consultant to the FDA Drug Safety and Risk Management Advisory Committee and member of the Methods Committee of the Patient Centered Outcomes Research Institute.

He received his medical training at the University of Munich Medical School and his doctoral degree in Pharmacoepidemiology from Harvard.

Sessions

Precision Medicine Salon H-K
Sebastian Schneeweiss (Brigham and Women’s Hospital, Division of Pharmacoepidemiology and Pharmacoeconomics )
Average rating: ****.
(4.00, 1 rating)
Dr. Sebastian Schneeweiss, Harvard Medical School and Brigham and Women’s Hospital, will discuss how analytic capabilities for big data, based on principles of causal inference, are currently being used in his organization to make a big impact in drug safety and effectiveness. He is also Co-chair of the FDA’s Mini-Sentinel methods program, a post-market medical product safety assessment program. Read more.

For exhibition and sponsorship opportunities at Strata Rx conference, contact Sharon Pierce at (203) 304-9476 or spierce@oreilly.com

For information on trade opportunities with O'Reilly conferences email mediapartners
@oreilly.com

View a complete list of Strata Rx 2013 contacts